Category
February 25, 2020
Dr. Manjeet Rao, Greehey CCRI Deputy Director (interim), was recently awarded a grant from National Cancer Institute ($2.1 million) to test the therapeutic efficacy of a novel drug that can inhibit the function of a protein that is highly expressed in cancers. Cancer cells use various mechanisms to manage their survival such as repairing DNA […]
February 24, 2020
Paige Baldwin1, Rostislav Likhotvorik2, Nabeela Baig2, Jodie Cropper2, Ruth Carlson2, Raushan Kurmasheva2,3*† and Srinivas Sridhar1,4,5*† The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both preclinical and clinical […]
February 24, 2020
Written by: Will Sansom An award of $1.2 million from the Cancer Prevention and Research Institute of Texas (CPRIT) went to Greehey CCRI Deputy Director and principal investigator Manjeet Rao, PhD, professor of cell systems and anatomy, for studies of an enzyme protein that helps osteosarcoma cells to survive and spread. The team, which includes co-principal investigator Yogesh Gupta, […]
February 22, 2020
“Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles” Abstract Therapy resistance and recurrence in high-grade gliomas are driven by their populations of glioma stem cells (GSCs). Thus, detailed molecular characterization of GSCs is needed to develop more effective therapies. We conducted a study to identify differences in the splicing […]
February 20, 2020
CPRIT officials said this is one of the largest collective awards the Alamo City has received in a single funding round.
February 18, 2020
Michael A. Liss,1 Yidong Chen,2 Ronald Rodriguez,1 Deepak Pruthi,1 Teresa Johnson-Pais,3 Hanzhang Wang,1 Ahmed Mansour,1 James R. White,4 and Dharam Kaushik1 Abstract Objective. To perform a proof of concept microbiome evaluation and PD-L1 expression profiling in clear-cell renal cell carcinoma (cc-RCC) with associated tumor thrombus (TT). Methods. After IRB approval, six patients underwent radical nephrectomy (RN) with venous tumor thrombectomy (VTT). We collected fresh tissue […]
February 6, 2020
Zhe Zhu, Pinar Mesci, Jean A Bernatchez, Ryan C Gimple, Xiuxing Wang, Simon T Schafer, Hiromi I Wettersten, Sungjun Beck, Alex E Clark, Qiulian Wu, Briana C Prager, Leo JY Kim, Rekha Dhanwani, Sonia Sharma, Alexandra Garancher, Sara M Weis, Stephen C Mack, Priscilla D Negraes, Cleber A Trujillo, Luiz O Penalva, Jing Feng, Zhou […]
January 11, 2020
Samson Ghilu, Qilin Li, Shaun D. Fontaine, Daniel V. Santi, Raushan T. Kurmasheva, Siyuan Zheng & Peter J. Houghton Abstract Purpose Defining robust criteria for drug activity in preclinical studies allows for fewer animals per treatment group, and potentially allows for the inclusion of additional cancer models that more accurately represent genetic diversity and, potentially, allows for tumor sensitivity biomarker identification. Methods […]
January 2, 2020
Sulgi Park, Chung-Seog Song, Chun-Lin Lin, Shoulei Jiang, Pawel A Osmulski, Chiou-Miin Wang, Brett T Marck, Alvin M Matsumoto, Colm Morrissey, Maria E Gaczynska, Yidong Chen, Elahe A Mostaghel, Bandana Chatterjee Abstract SULT2B1b (SULT2B) is a prostate-expressed hydroxysteroid sulfotransferase, which may regulate intracrine androgen homeostasis by mediating 3β-sulfation of dehydroepiandrosterone (DHEA), the precursor for 5α-dihydrotestosterone (DHT) biosynthesis. The aldo-keto reductase (AKR)1C3 regulates androgen receptor (AR) activity in […]
January 2, 2020
Gail E Tomlinson 1 Abstract The cytogenetics of hepatoblastoma demonstrate recurring events which include whole chromosome trisomies, most commonly trisomy of chromosome 2, 8, or 10. In addition, unbalanced translocations involving a breakpoint on the proximal short arm of chromosome 1 are observed which results in a duplication of the long arm of chromosome 1q. The […]